This was the stock's fourth consecutive day of gains.

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals is working on a trial to use stem cells to treat type 1 diabetes, with encouraging results so far. As research continues, stem-cell therapies are on track to revolutionise ...

Catch up on all the latest pharma industry news from the past month, from breakthroughs in gene therapy to promising drug ...

We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.